ACADIA Pharmaceuticals (ACAD) News Today $16.87 +0.14 (+0.84%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025December 19 at 4:05 PM | businesswire.comACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Down 2.9% - What's Next?ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Down 2.9% - Should You Sell?December 19 at 1:21 PM | marketbeat.comState Street Corp Purchases 173,084 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)State Street Corp grew its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 3.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,973,874 shares of the biophaDecember 17, 2024 | marketbeat.comAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 16, 2024 | businesswire.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Position Reduced by Fmr LLCFmr LLC decreased its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 95.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,358 shares of theDecember 16, 2024 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock Position Decreased by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd lowered its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 43.7% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 50,544 shares of the biopharmaceutical company's stDecember 14, 2024 | marketbeat.comACADIA Pharmaceuticals Completes Sale of Rare Pediatric Disease Priority Review VoucherDecember 14, 2024 | americanbankingnews.comNeo Ivy Capital Management Has $54,000 Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Neo Ivy Capital Management cut its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 98.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,482 shares of the biopharmaceuticaDecember 13, 2024 | marketbeat.comNeuren Pharmaceuticals Gains from Acadia’s $150M Voucher SaleDecember 12, 2024 | markets.businessinsider.comAcadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 MillionDecember 11, 2024 | businesswire.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives $25.56 Consensus Target Price from AnalystsDecember 11, 2024 | americanbankingnews.comAnalysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Agios Pharma (AGIO)December 9, 2024 | markets.businessinsider.comWalleye Capital LLC Sells 74,524 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Walleye Capital LLC decreased its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 64.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,806 shares of the biopharmaceutDecember 8, 2024 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from AnalystsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seventeen research firms that are covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating tDecember 8, 2024 | marketbeat.comAcadia (ACAD) Down 2.9% Since Last Earnings Report: Can It Rebound?December 6, 2024 | uk.finance.yahoo.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company decreased its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 10.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 413,269 sharesDecember 6, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Sells 143,688 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Jacobs Levy Equity Management Inc. lessened its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 10.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,211,314 shares of the bioDecember 5, 2024 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Holdings Boosted by BNP Paribas Financial MarketsBNP Paribas Financial Markets boosted its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 259.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 223,618 shares of the biopharmaceutical companDecember 5, 2024 | marketbeat.com242,300 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Purchased by Erste Asset Management GmbHErste Asset Management GmbH purchased a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 242,300 shares of the biopharmaceutical company's stock, vDecember 3, 2024 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Up 7.5% in NovemberACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 10,240,000 shares, an increase of 7.5% from the October 31st total of 9,530,000 shares. Based on an average trading volume of 1,330,000 shares, the days-to-cover ratio is currently 7.7 days.December 3, 2024 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stake Boosted by Edgestream Partners L.P.Edgestream Partners L.P. increased its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 141.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 219,329 shares of the biopharmaceuticalDecember 2, 2024 | marketbeat.comRockefeller Capital Management L.P. Buys 185,684 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Rockefeller Capital Management L.P. grew its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 19.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,139,934 shares of the biopharmaceutical companyDecember 2, 2024 | marketbeat.comIntech Investment Management LLC Makes New Investment in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Intech Investment Management LLC purchased a new stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 37,683 shares of the biopharmaceutDecember 2, 2024 | marketbeat.comResearch Analysts Set Expectations for ACAD FY2024 EarningsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Research analysts at Zacks Research raised their FY2024 earnings per share estimates for ACADIA Pharmaceuticals in a research report issued on Wednesday, November 27th. Zacks Research analyst A. Chakraborty now anticipates that the biopharDecember 2, 2024 | marketbeat.comFred Alger Management LLC Grows Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Fred Alger Management LLC lifted its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 17.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,186,389 shares of the biophNovember 29, 2024 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stake Raised by Fisher Asset Management LLCFisher Asset Management LLC boosted its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 19.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 194,599 shares of the biNovember 29, 2024 | marketbeat.comAcadia Pharma Announces License Agreement With Saniona For SAN711November 27, 2024 | markets.businessinsider.comAcadia signs licensing deal for essential tremor drug candidateNovember 26, 2024 | msn.comAcadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711November 26, 2024 | marketwatch.comAcadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711November 26, 2024 | businesswire.comB. Metzler seel. Sohn & Co. Holding AG Invests $483,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The fund acquired 31,405 shares of the biopharmaceutical company's stock, valued at approxNovember 25, 2024 | marketbeat.comPrincipal Financial Group Inc. Acquires 52,340 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Principal Financial Group Inc. lifted its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 67.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 129,551 shNovember 23, 2024 | marketbeat.comAcadia Pharmaceuticals Announces Leadership Change Amid COO DepartureNovember 21, 2024 | markets.businessinsider.comACADIA Pharmaceuticals: Strategic Leadership and Growth Prospects Support Buy RatingNovember 21, 2024 | markets.businessinsider.comAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesNovember 21, 2024 | businesswire.comAcadia Pharmaceuticals' Operating Chief Involuntarily Terminated Without CauseNovember 21, 2024 | marketwatch.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stake Decreased by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. decreased its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 22.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 972,665 shares of the biopharmaceuticaNovember 21, 2024 | marketbeat.comFY2027 Earnings Forecast for ACAD Issued By Leerink PartnrsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities researchers at Leerink Partnrs dropped their FY2027 earnings per share estimates for ACADIA Pharmaceuticals in a report released on Sunday, November 17th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceuticalNovember 20, 2024 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider Sells $68,467.13 in StockNovember 20, 2024 | insidertrades.comACADIA Pharmaceuticals: Untapped Potential with Financial Stability and Strategic Growth OpportunitiesNovember 19, 2024 | markets.businessinsider.comFY2024 Earnings Estimate for ACAD Issued By Leerink PartnrsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Analysts at Leerink Partnrs decreased their FY2024 earnings per share estimates for shares of ACADIA Pharmaceuticals in a research report issued on Sunday, November 17th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmacNovember 19, 2024 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Large Growth in Short InterestACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 9,530,000 shares, a growth of 16.5% from the October 15th total of 8,180,000 shares. Based on an average daily volume of 1,360,000 shares, the short-interest ratio is currently 7.0 days.November 16, 2024 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock Holdings Lessened by GSA Capital Partners LLPGSA Capital Partners LLP cut its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 62.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 67,096 shares of the biophNovember 16, 2024 | marketbeat.comAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 15, 2024 | businesswire.comCentessa Pharmaceuticals (CNTA) Receives a Buy from Morgan StanleyNovember 14, 2024 | markets.businessinsider.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) have earned an average rating of "Moderate Buy" from the seventeen analysts that are presently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and eleven have giveNovember 13, 2024 | marketbeat.comUS Bancorp DE Has $507,000 Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)US Bancorp DE boosted its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 2,084.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,934 shares of the biopharmaceuticalNovember 12, 2024 | marketbeat.comAcadia Pharmaceuticals: Proving The Naysayers WrongNovember 11, 2024 | seekingalpha.comWhat is Leerink Partnrs' Forecast for ACAD FY2026 Earnings?ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Research analysts at Leerink Partnrs lifted their FY2026 earnings estimates for ACADIA Pharmaceuticals in a report issued on Wednesday, November 6th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will poNovember 11, 2024 | marketbeat.comEquities Analysts Issue Forecasts for ACAD FY2024 EarningsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Research analysts at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a research report issued to clients and investors on Thursday, November 7th. HC Wainwright analyst A. Fein now anticipNovember 11, 2024 | marketbeat.com Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy. Click to get the name and ticker symbol ACAD Media Mentions By Week ACAD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACAD News Sentiment▼0.750.60▲Average Medical News Sentiment ACAD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACAD Articles This Week▼57▲ACAD Articles Average Week Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Catalent News Vaxcyte News Qiagen News Intra-Cellular Therapies News Roivant Sciences News Ascendis Pharma A/S News Revolution Medicines News Lantheus News Legend Biotech News Nuvalent News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACAD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACAD Stock Alerts